| Species |
Human |
| Protein Construction |
LILRA5/CD85f/ILT11 (Gly42-Arg268)_x000D_
Accession # A6NI73-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
28.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs). Human LILRA5, also known as ILT11, LIR-9, and CD85f, consists of a 227 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 10 aa cytoplasmic tail. LILRA5 may play a role in triggering innate immune responses. Does not seem to play a role for any class I MHC antigen recognition. |
| Synonyms |
CD85; CD85f; ILT11; ILT-11; ILT11CD85f; LILRA5; LILRB7; LIR9; LIR-9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
